Revision of PRECAUTIONS

Hydrocortisone sodium succinate (preparations not indicated for lymphoid tumours)
Hydrocortisone sodium phosphate

January 10, 2024

Therapeutic category
Adrenal hormone preparations

Non-proprietary name
Hydrocortisone sodium succinate (preparations not indicated for lymphoid tumours)
Hydrocortisone sodium phosphate

Safety measure
PRECAUTIONS should be revised.
Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director-General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

<table>
<thead>
<tr>
<th>Current</th>
<th>Revision</th>
</tr>
</thead>
<tbody>
<tr>
<td>Important Precautions (N/A)</td>
<td>Important Precautions</td>
</tr>
<tr>
<td></td>
<td>It has been reported that tumour lysis syndrome occurred when hydrocortisone preparations (injections) were administered to patients with lymphoid tumours. If rapid electrolyte abnormalities, acute kidney injury, etc. are observed after administration of this drug, appropriate measures should be taken with consideration given to the possibility of tumour lysis syndrome.</td>
</tr>
</tbody>
</table>

Note: Hydrocortisone sodium succinate (preparations not indicated for lymphoid tumours) and hydrocortisone sodium phosphate are designated as drugs requiring preparation of a Drug Guide for Patients.

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, PSEHB Notification No. 0611-1 by the Director-General of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.

<table>
<thead>
<tr>
<th>Current</th>
<th>Revision</th>
</tr>
</thead>
<tbody>
<tr>
<td>8. IMPORTANT PRECAUTIONS (N/A)</td>
<td>8. IMPORTANT PRECAUTIONS</td>
</tr>
<tr>
<td></td>
<td>It has been reported that tumour lysis syndrome occurred when hydrocortisone preparations (injections) were administered to patients with lymphoid tumours. If rapid electrolyte abnormalities, acute kidney injury, etc. are observed after administration of this drug, appropriate measures should be taken with consideration</td>
</tr>
</tbody>
</table>

Pharmaceuticals and Medical Devices Agency
3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp
given to the possibility of tumour lysis syndrome.

Note: Hydrocortisone sodium succinate (preparations not indicated for lymphoid tumours) and hydrocortisone sodium phosphate are designated as drugs requiring preparation of a Drug Guide for Patients.

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.